- Home
- BIIB vs CMS Comparison
BIIB vs CMS Comparison
Compare BIIB & CMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- CMS
- Stock Information
- Founded
- BIIB 1978
- CMS 1987
- Country
- BIIB United States
- CMS United States
- Employees
- BIIB 7605
- CMS N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- CMS Power Generation
- Sector
- BIIB Health Care
- CMS Utilities
- Exchange
- BIIB Nasdaq
- CMS Nasdaq
- Market Cap
- BIIB 20.6B
- CMS 20.8B
- IPO Year
- BIIB 1991
- CMS N/A
- Fundamental
- Price
- BIIB $140.60
- CMS $71.51
- Analyst Decision
- BIIB Buy
- CMS Buy
- Analyst Count
- BIIB 27
- CMS 12
- Target Price
- BIIB $220.50
- CMS $71.58
- AVG Volume (30 Days)
- BIIB 1.5M
- CMS 2.3M
- Earning Date
- BIIB 02-12-2025
- CMS 02-06-2025
- Dividend Yield
- BIIB N/A
- CMS 3.03%
- EPS Growth
- BIIB 40.28
- CMS 10.57
- EPS
- BIIB 11.18
- CMS 3.33
- Revenue
- BIIB $9,675,900,000.00
- CMS $7,515,000,000.00
- Revenue This Year
- BIIB N/A
- CMS $9.69
- Revenue Next Year
- BIIB $1.57
- CMS $3.15
- P/E Ratio
- BIIB $12.65
- CMS $21.49
- Revenue Growth
- BIIB N/A
- CMS 0.71
- 52 Week Low
- BIIB $128.51
- CMS $56.31
- 52 Week High
- BIIB $238.00
- CMS $72.40
- Technical
- Relative Strength Index (RSI)
- BIIB 44.88
- CMS 70.31
- Support Level
- BIIB $135.02
- CMS $68.74
- Resistance Level
- BIIB $141.69
- CMS $70.03
- Average True Range (ATR)
- BIIB 4.00
- CMS 1.17
- MACD
- BIIB 0.04
- CMS 0.35
- Stochastic Oscillator
- BIIB 59.44
- CMS 93.79
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About CMS CMS Energy Corporation
CMS Energy is an energy holding company with three principal businesses. Its regulated utility, Consumers Energy, provides regulated natural gas service to 1.8 million customers and electric service to 1.9 million customers in Michigan. NorthStar Clean Energy, formerly CMS Enterprises, is engaged in wholesale power generation, including contracted renewable energy. CMS sold EnerBank in October 2021.